Elranatamab is a bi-specific T-cell engaging antibody that binds CD3-epsilon on T-cells and B-cell maturation antigen (BCMA) on plasma cells, plasmablasts, and multiple myeloma cells. Binding of elranatamab to BCMA on tumour cells and CD3 on T-cells is independent of native T-cell receptor (TCR) specificity or reliance on major histocompatibility (MHC) Class 1 molecules. Elranatamab activated T-cells, led to proinflammatory cytokine release, and resulted in multiple myeloma cell lysis.
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):
| Title | Information Source | Document Type | |
|---|---|---|---|
| ELREXFIO Solution for injection | FDA, National Drug Code (US) | MPI, US: SPL/PLR | |
| ELREXFIO Solution for injection | European Medicines Agency (EU) | MPI, EU: SmPC |
Elranatamab is an active ingredient of these brands:
United States (US)Austria (AT)Croatia (HR)Estonia (EE)France (FR)Lithuania (LT)Romania (RO)Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide. |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
